
Sign up to save your podcasts
Or


In this episode, we explore a surprising new contender in the fight against alcohol use disorder — semaglutide. Could the blockbuster weight-loss drug also curb heavy drinking? We examine the first randomized controlled trial testing this GLP-1 receptor agonist specifically for AUD.
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D.
By Psychopharmacology Institute4.6
271271 ratings
In this episode, we explore a surprising new contender in the fight against alcohol use disorder — semaglutide. Could the blockbuster weight-loss drug also curb heavy drinking? We examine the first randomized controlled trial testing this GLP-1 receptor agonist specifically for AUD.
Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D.

56 Listeners

75 Listeners

504 Listeners

141 Listeners

12,730 Listeners

2,528 Listeners

3,374 Listeners

158 Listeners

1,363 Listeners

10,331 Listeners

566 Listeners

489 Listeners

756 Listeners

200 Listeners

152 Listeners